期刊文献+

Simultaneous determination of doxorubicin and its dipeptide prodrug in mice plasma by HPLC with fluorescence detection 被引量:3

Simultaneous determination of doxorubicin and its dipeptide prodrug in mice plasma by HPLC with fluorescence detection
下载PDF
导出
摘要 A simple and sensitive high performance liquid chromatography with fluorescence detection(HPLC–FD)has been developed for simultaneous quantification of doxorubicin(DOX) and its dipeptide conjugate prodrug(PDOX) in mice plasma.The chromatographic separation was carried out on an Amethyst C_(18)–H column with gradient mobile phase of 0.1% formic acid and 0.1% formic acid in acetonitrile at a flow rate of 1.0 mL/min.The excitation and emission wavelengths were set at 490 and 550 nm,respectively.The method was comprehensively validated.The limits of detection were low up to 5.0 ng/m L for DOX and 25.0 ng/m L for PDOX.And the limits of quantification were low up to 12.5 ng/m L for DOX and 50 ng/m L for PDOX,which were lower than those for most of the current methods.The calibration curves showed good linearity(R^2>0.999) over the concentration ranges.The extraction recoveries ranged from 84.0% to 88.2% for DOX and from 85.4% to 89.2% for PDOX.Satisfactory intra-day and inter-day precisions were achieved with RSDs less than 9.1%.The results show that the developed HPLC–FD method is accurate,reliable and will be helpful for preclinical pharmacokinetic study of DOX and PDOX. A simple and sensitive high performance liquid chromatography with fluorescence detection (HPLC-FD) has been developed for simultaneous quantification of doxorubicin (DOX) and its dipeptide conjugate prodrug (PDOX) in mice plasma. The chromatographic separation was carried out on an Amethyst C18-H column with gradient mobile phase of 0.1% formic acid and 0.1% formic acid in acetonitrile at a flow rate of 1.0 mL/min. The excitation and emission wavelengths were set at 490 and 550 nm, respectively. The method was comprehensively validated. The limits of detection were low up to 5.0 ng/mL for DOX and 25.0 ng/mL for PDOX. And the limits of quantification were low up to 12.5 ng/mL for DOX and 50 ng/mL for PDOX, which were lower than those for most of the current methods. The calibration curves showed good linearity (R2 〉 0.999) over the concentration ranges. The extraction recoveries ranged from 84.0% to 88.2% for DOX and from 85.4% to 89.2% for PDOX. Satisfactory intra-day and inter-day precisions were achieved with RSDs less than 9.1%. The results show that the developed HPLC-FD method is accurate, reliable and will be helpful for preclinical pharmacokinetic study of DOX and PDOX.
出处 《Journal of Pharmaceutical Analysis》 SCIE CAS 2016年第3期199-202,共4页 药物分析学报(英文版)
基金 supported by the National Natural Science Foundation of China (Grant nos. 21375101, 81573384 and 91417301) Natural Science Foundation of Hubei Province, China (No. 2014CFA077) Innovation Seed Fund and Translational Medical Research Fund of Wuhan University School of Medicine, China
关键词 高效液相色谱 荧光检测法 阿霉素 同时测定 前体药物 血浆 小鼠 二肽 Doxorubicin Doxorubicin's dipeptide prodrug HPLC-FD Mice plasma
  • 相关文献

参考文献18

  • 1P. Zhang, J. Li, M. Ghazwani, et al., Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemother- apy, Biomaterials 67 (2015) 104-114.
  • 2C. Carvalho, R.X. Santos, S. Cardoso, et al., Doxorubicin: the good, the bad and the ugly effect, Curr. Med. Chem. 16 (2009) 3267-3285.
  • 3Y. Chen, Y. Wan, Y. Wang, et al., Anticancer efficacy enhancement and at- tenuation of side effects of doxorubicin with titanium dioxide nanoparticles, Int. J. Nanomed. 6 (2011) 2321-2326.
  • 4G, Du, H. Lin, M. Wang, et al,, Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-lot in tumor and normal cells, Cancer Chemoth. PharmacoL 65 (2010) 277-287.
  • 5R. Graeser, N. Esser, H. Unger, et al., INNO-206, the (6-maleimidocaproyl hy- drazone derivative of doxorubicin), shows superior antitumor efficacy com- pared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model, Invest. New Drugs 28 (2010) 14-19.
  • 6C. Mamot, R. Ritschard, A. Wicki, et al., Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid turnouts: a phase 1 dose-escalation study, Lancet Oncol, 13 (2012) 1234-1241.
  • 7Y.-J. Zhong, L.-H. Shao, Y. Li, Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review), Int. J. Oncol. 42 (2013) 373-383.
  • 8LH. Shao, S.P. Liu, J.X. Hou, et al., Cathepsin B cleavable novel prodrug Ac-Phe- Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis, Cancer 118 (2012) 2986-2996,.
  • 9N.D. Rawlings, A.J. Barrett, A. Bateman, MEROPS: the peptidase database, Nucleic Acids Res. 38 (2010) 227-233.
  • 10M.A. Nouh, M.M. Mohamed, M. EI-Shinawi, et al,, Cathepsin B: a potential prognostic marker for inflammatory breast cancer, J. Transl. Med. 9 (2011) 1-8.

同被引文献8

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部